See more : PT Millennium Pharmacon International Tbk (SDPC.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Zomedica Corp. (ZOM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zomedica Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Lake Victoria Gold Ltd. (LVG.V) Income Statement Analysis – Financial Results
- Hawaiian Holdings, Inc. (HA) Income Statement Analysis – Financial Results
- SBA Communications Corporation (0KYZ.L) Income Statement Analysis – Financial Results
- Persimmon Plc (PSMMF) Income Statement Analysis – Financial Results
- DCM Limited (DCM.BO) Income Statement Analysis – Financial Results
Zomedica Corp. (ZOM)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zomedica.com
About Zomedica Corp.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.19M | 18.93M | 4.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 7.87M | 5.28M | 1.08M | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 17.32M | 13.65M | 3.05M | -530.02K | -787.61K | -205.77K | -92.41K | -45.82K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 68.76% | 72.12% | 73.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.74M | 2.58M | 1.67M | 8.04M | 10.35M | 10.32M | 2.75M | 1.52M | 758.05K | 0.00 | 0.00 |
| General & Administrative | 29.03M | 22.93M | 0.00 | 7.93M | 8.18M | 5.83M | 5.08M | 4.24M | 1.43M | 42.41K | 77.50K |
| Selling & Marketing | 14.14M | 9.88M | 0.00 | 261.91K | 471.89K | 225.89K | 164.25K | 194.19K | 143.47K | 0.00 | 0.00 |
| SG&A | 43.17M | 33.00M | 22.75M | 8.19M | 8.65M | 6.06M | 5.24M | 4.43M | 1.57M | 42.41K | 77.50K |
| Other Expenses | 0.00 | -7.00K | 6.00K | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.91M | 35.58M | 24.43M | 16.76M | 19.78M | 16.58M | 8.08M | 6.00M | 2.28M | 42.41K | 77.50K |
| Cost & Expenses | 56.78M | 40.85M | 25.51M | 16.76M | 19.78M | 16.58M | 8.08M | 6.00M | 2.28M | 42.41K | 77.50K |
| Interest Income | 5.46M | 2.70M | 357.45K | 32.86K | 18.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 175.00K | 1.00K | 6.05K | 732.00 | 18.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.30M | 4.04M | 1.14M | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 9.05K | 0.00 | 0.00 |
| EBITDA | -29.39M | -15.34M | -19.57M | -16.38M | -19.00M | -16.44M | -7.97M | -5.97M | -2.28M | -42.41K | -77.50K |
| EBITDA Ratio | -116.68% | -80.23% | -479.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.59M | -21.92M | -21.37M | -16.76M | -19.78M | -16.58M | -8.08M | -6.00M | -2.29M | -42.41K | -77.50K |
| Operating Income Ratio | -125.43% | -115.81% | -517.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.27M | 2.54M | 657.78K | -146.81K | 273.00 | -68.44K | 18.98K | 258.06K | 7.44K | 0.00 | 0.00 |
| Income Before Tax | -35.86M | -19.38M | -20.72M | -16.91M | -19.78M | -16.65M | -8.07M | -6.01M | -2.28M | -42.41K | -77.50K |
| Income Before Tax Ratio | -142.38% | -102.38% | -501.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.33M | -2.37M | -2.33M | 9.33K | 38.08K | 136.88K | -18.98K | 28.59K | 0.00 | 0.00 | 0.00 |
| Net Income | -34.53M | -17.02M | -18.38M | -16.92M | -19.82M | -16.65M | -8.07M | -6.01M | -2.28M | -42.41K | -77.50K |
| Net Income Ratio | -137.10% | -89.88% | -444.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.02 | -0.02 | -0.05 | -0.19 | -0.18 | -0.09 | -0.08 | -0.05 | -0.04 | -0.23 |
| EPS Diluted | -0.04 | -0.02 | -0.02 | -0.05 | -0.19 | -0.18 | -0.09 | -0.08 | -0.05 | -0.04 | -0.23 |
| Weighted Avg Shares Out | 979.95M | 979.92M | 956.53M | 364.44M | 106.30M | 92.49M | 87.40M | 80.16M | 46.23M | 1.00M | 336.99K |
| Weighted Avg Shares Out (Dil) | 979.95M | 979.92M | 956.53M | 364.44M | 106.30M | 93.44M | 87.40M | 80.16M | 46.23M | 1.00M | 336.99K |
The United States Eventing Association Names Zomedica's PulseVet(R) as the Official Shock Wave of the USEA
Zomedica will sponsor a variety of high-profile events within the USEA ANN ARBOR, MI / ACCESSWIRE / July 17, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for...
Zomedica Expands Global Reach Through Strategic Alliance with Leader Healthcare Group for Sales Expansion in Key International Markets
Leader Healthcare Group is Chosen as Distribution Partner to Launch Zomedica ® Products into the Gulf Cooperation Council Countries in the Middle East & North Africa (MENA), and India ANN ARBOR, MI / ACCESSWIRE / July 9, 2024 / Zomedica...
US Equestrian Names Zomedica's PulseVet System as the Official Shock Wave Therapy of US Equestrian Team Veterinarians
PulseVet ® Shock Wave Device Supports Equine Athletes Ahead of Major International Team Events ANN ARBOR, MI / ACCESSWIRE / July 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and...
Zomedica Expands TRUFORMA Addressable Market with Launch of Equine Cortisol Assay for the Platform
First-of-its-kind stall-side testing to enable rapid, life-saving decisions for equine veterinarians ANN ARBOR, MI / ACCESSWIRE / June 27, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for equine...
Zomedica Expands Market Opportunity for the TRUFORMA Point-of-Care Diagnostic Platform by Securing CE Mark
CE mark enables launch of the TRUFORMA® Diagnostic Platform into the European Union ANN ARBOR, MI / ACCESSWIRE / June 25, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic...
The 3 Most Undervalued Penny Stocks to Buy in June 2024
Recent trading activity suggests that penny stocks are in the spotlight. According to the Financial Times, stocks priced below $1 have comprised more than 14% of 2024's trading volume thus far, illustrating the growing demand for penny stocks.
Zomedica to Present at the Sidoti Small Cap Conference June 12, 2024
ANN ARBOR, MI / ACCESSWIRE / June 10, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Peter Donato, EVP and...
Zomedica Announces Presentation of Compelling TRUFORMA(R) Research Findings and Educational Programs at Major Veterinary Internal Medicine Conference
New research data confirms superiority of TRUFORMA's Bulk Acoustic Wave Sensor technology in diagnosing feline hyperthyroidism ANN ARBOR, MI / ACCESSWIRE / June 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care...
Zomedica Increases Manufacturing Capacity with Expansion of its Roswell, Georgia Facility; Can Support Production to Five times Current Levels
Timely expansion enhances capacity amidst rapid sales growth ANN ARBOR, MI / ACCESSWIRE / June 4, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for equine and companion animals,...
Zomedica Releases Over-the-Air Software Update Capabilities for Its TRUFORMA(R) Platform
OTA capability enhances introduction of new assays from rapidly expanding menu ANN ARBOR, MI / ACCESSWIRE / May 15, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for...
Source: https://incomestatements.info
Category: Stock Reports
How has Zomedica’s diagnostic product revenue grown?
Zomedica (NYSE:ZOM) reported Q3 2024 financial results with revenue growing 10% to $7.0 million, maintaining a strong gross margin of 72.3%. The Diagnostics segment grew 38%, while the Therapeutic Device segment increased 9%.
What were Zomedica’s revenue and losses in the last 12 months?
In the last 12 months, Zomedica had revenue of $26.73 million and -$62.19 million in losses. Loss per share was -$0.06.